Acrylates and methacrylates, though common in a wide variety of products, especially in the dental industry, can cause adverse skin reactions. These compounds, including 2-hydroxyethyl methacrylate, triethylene glycol dimethacrylate, and bisphenol A-glycidyl methacrylate, are strong contact irritants or allergens. Found in dental prostheses, composite resins, dentin bonding materials, and glass ionomers, they pose a higher risk of exposure for dental personnel. Clinically, acrylate allergies manifest as facial rashes, eczema with cracked skin on fingers (pulpitis), nail dystrophy, and periungual dermatitis. Recently, however, the highest frequency of allergic reactions to acrylates has been observed in the beauty industry due to increased use in artificial nails, eyelashes, and hair extensions. This has led to greater sensitization. Acrylates are also used in medical applications such as bone cement for orthopedic endoprostheses, soft contact lenses, hearing aids, histological preparations, and wound dressings, which can also cause allergic reactions. For example, acrylates in surgical glue can cause severe dermatitis, and diabetic medical devices are also potential sources of allergic contact dermatitis. Given the extensive use and prolonged skin contact of products containing acrylates and methacrylates, this review aims to present current knowledge from the literature on reactions to these compounds across different industries.

Background/Objectives/Methods: Atopic dermatitis (AD) impacts various aspects of patients’ lives including personal life, psychological aspects/disturbances (e.g., depression, anxiety, or even suicidal thoughts), school, and work-related activities, including career advancement. The aim of this narrative review is to present the latest information available on how to best approach AD patient management, as well as decisions regarding standard/advanced systemic therapy, by gathering evidence from the relevant medical literature (PubMed and other prominent medical databases). Results: Thus, AD patient management and decisions regarding advanced/systemic therapy are complex, requiring the consideration of multiple disease-related factors: age; disease severity; patient medical history and comorbidities; previous topical therapy use and any adverse reactions; treatment efficacy concerns; patient preferences, expectations and fears; pregnancy planning; ability and willingness to adhere to the treatment regimen; impact on related risks; and any associated psychological or psychiatric issues. Current guidelines and systematic reviews support the safety and efficacy of systemic therapy including conventional drugs (cyclosporine, methotrexate, and azathioprine), biologics (dupilumab and tralokinumab), and JAK inhibitors (baricitinib, upadacitinib, and abrocitinib) recommended for treating moderate and severe AD. Recently, additional biologics have been evaluated in clinical trials, including lebrikizumab, nemolizumab, eblasakimab, and OX40/OX40L, among others. Conclusions: The most recently suggested approach to treating AD patients suggests focusing on therapy that targets and achieves minimal disease activity (MDA), where therapy decisions are informed by both the patient and the clinician. Available data also indicate the importance of a personalized, stepwise, and multidisciplinary approach. This type of approach promotes patient compliance, satisfaction with therapy, and increased engagement, which all lead to better patient outcomes.

Acrylates and methacrylates are widely used, especially in the dental industry, but can cause adverse skin reactions. These compounds, including 2-hydroxyethyl methacrylate, triethylene glycol dimethacrylate, and bisphenol A-glycidyl methacrylate, are strong contact irritants or allergens. Found in dental prostheses, composite resins, dentin bonding materials, and glass ionomers, they pose a higher risk of exposure for dental personnel. Clinically, acrylate allergies manifest as facial rashes, eczema with cracked skin on fingers (pulpitis), nail dystrophy, and periungual dermatitis. Recently, the highest frequency of allergic reactions to acrylates has shifted from dentistry to the beauty industry due to increased use in artificial nails, eyelashes, and hair extensions. This has led to greater sensitization. Acrylates are also used in medical applications, such as bone cement for orthopedic endoprostheses, soft contact lenses, hearing aids, histological preparations, and wound dressings, which can also cause allergic reactions. Severe dermatitis from surgical glue containing acrylates has been documented, and diabetic medical devices are potential sources of allergic contact dermatitis. Given the extensive use and prolonged skin contact of products containing acrylates and methacrylates, this review aims to present current knowledge and literature on reactions to these compounds across different industries.

Background/Objectives: Adolescence is a sensitive period of development marked by significant changes. The quality of life (QoL) of adolescents with atopic dermatitis (AD) can be substantially impacted by the disease. The chronic nature of AD is particularly significant: due to recurring (relapsing) skin lesions, adolescents are likely exposed to greater stress and depressive symptoms than those experiencing transient or one-time symptoms. Aesthetic and functional AD skin lesions during adolescence lead to reduced happiness, high stress and depression. Methods: In this review, we wanted to present the current knowledge on mental health, psychological features and psychiatric comorbidity of adolescents with AD, based on the previous studies/research on this topic presented in the PubMed database. Results: Previous studies have confirmed that sleep disturbances, behavioral disorders, internalizing profiles, depression and anxiety, stress symptoms and suicidality represent the most prevalent psychiatric comorbidities and psychological features in adolescents with AD. According to research data, adolescents with AD also reported a tendency toward feelings of sadness and hopelessness, and even suicidal thoughts and attempts. The relationship between sleep disturbances, psychiatric disorders, and suicidality in adolescents with AD is complex and multifaceted. Conclusions: Adequate social competencies are essential for healthy mental development, as their impairments may be associated with psychological alterations or psychiatric disorders in childhood and adolescence that potentially persist into adulthood. These findings highlight the need for continuous psychological evaluation and the implementation of intervention programs from an early age. Psychological interventions, such as cognitive behavioral therapy, accompanied by psychopharmaceuticals, such as selective serotonin reuptake inhibitors (when indicated), seem to be the most beneficial treatment options in AD patients who have the most frequent psychiatric comorbidities: depression and anxiety.

Atopic dermatitis (AD) impacts various aspects of patients' lives. The most reported factors affecting clinical burden are itching and psychological disturbances (e.g., depression, anxiety or even suicidal thoughts). Also, AD affects school and work-related activities, even career advancement. Thus, AD patient management and decisions regarding advanced/systemic therapy are complex, requiring consideration of multiple disease-related factors: age; disease severity; patient medical history and comorbidities; previous topical therapy use and any adverse reactions; treatment efficacy concerns; patient preferences, expectations and fears; pregnancy planning; ability and willingness to adhere to the treatment regimen; impact on intimate and social relationships and work/school performance; and treatment-related risks and any associated psychological or psychiatric issues. Current guidelines and systematic reviews support the safety and efficacy of systemic therapy (conventional, biologics, JAK inhibitors) for treating AD. When topical therapy and phototherapy are insufficient, conventional systemic therapies (cyclosporine, methotrexate, azathioprine) are used, or advanced treatments can be introduced, like biologics and JAK inhibitors (baricitinib, upadacitinib, and abrocitinib), which have been approved for moderate to severe AD. Additional biologics being evaluated in clinical trials include lebrikizumab, nemolizumab, eblasakimab, and OX40/OX40L. Ultimately, there is great value in a personalized and multidisciplinary approach to AD management, as has been supported by numerous studies and clinical practice over time.

Background/Objectives :Adolescence is a particularly sensitive period of development, marked by numerous changes, and the adolescent` quality of life (QoL) could be significantly affected by the disease like atopic dermatitis (AD). The chronic nature of AD is particularly significant : d ue to recurring (relapsing) skin lesions, adolescents are likely exposed to greater stress and depressive symptoms than those experiencing transient or one-time symptoms. Aesthetic and functional AD skin lesions during adolescence lead to reduced happiness, high stress and depression. Methods: In this review we wanted to present the current knowledge on mental health, psychological features and psychiatric comorbidity of adolescents with AD, based on the previous studies/research on this topic presented in Pubmed basis . Results: Previous studies have confirmed that sleep disturbances, behavioural disorders, internalizing profiles, depression and anxiety, stress symptoms and suicidality represent the most prevalent psychiatric comorbidities and psychological features in adolescents with AD. According to research data, adolescents with AD also reported a tendency toward feelings of sadness and hopelessness and even suicidal thoughts and attempts. The interplay between sleep disturbances, depression and anxiety, behavioural disorders as well as suicidality (as the most frequent psychiatric comorbidity in adolescents with AD) seems to be rather complex. Conclusions: So, a dequate social competence is essential for healthy mental development, as its impairment may be associated with psychological disorders in childhood and adolescence and potentially persist into adulthood. These findings highlight the need for a psychological approach and the introduction of intervention programs from an early age, such as mental health assessments and professional supervision following diagnosis.